On November 12, 2019, Impact 1st Taimei Technology Pharmacovigilance Frontier Summit was successfully held in Guangzhou. Over 300 industry professionals were presented at the summit. Experts in the field of Pharmacovigilance engaged in heated discussions and debated on topics such as development and trends of domestic pharmacovigilance, the successful practices and challenges faced by various pharmaceutical companies, the needs of medical institutions, and multi-party cooperation and innovation. In addition, Taimei Technology unveiled its comprehensive pharmacovigilance solutions at the summit.
Liu Weihuan, deputy dean of Hainan Cancer Hospital, Ye Lika, director of the Clinical Research Management Center of the Second Affiliated Hospital of Guangzhou Medical University, Zhang Shuaihua, deputy dean of HEC Research Institute, and Zhao Lu, CEO of Taimei Technology, gave their speeches on the summit.
The hotspots of the global pharmacovigilance discussions in 2019 focus on the topics of collaboration, technology, and the essential understanding of PV. Mr. Wan Bangxi, vice president of Taimei Technology, said that as the earliest domestic company providing pharmacovigilance systems and services, Taimei has accompanied the budding and growth of Chinese pharmacovigilance. Taimei Links various stakeholders in the industry and has served over 350 customers and operated more than 400 projects. The number of eSafety pharmacovigilance system visits is almost 200,000 and will maintain an upward trend.
Regarding the developing trend of pharmacovigilance in China, Ms. Dai Chenxian, director of pharmacovigilance of Sihuan Pharmaceutical Group, believes that the future of pharmacovigilance in China will be determined by the industry trends such as China’s drug regulation, increase of innovative drugs, the transformation or relocation of pharmaceutical companies, and the integration of international standard and domestic regulation characteristics. And the PV system will take MAH as the main body with multi-party participation in the future.
Subsequently, Mr. Zhong Guoping, Director of the Institute of Clinical Pharmacology, Sun Yat-sen University, Mr. Cao Yong, Director of the Sun Yat-sen University Cancer Center, Mr. Zhang Xiaole, Chairman of PSM Beijing Foundation, Mr. Zhu Jie, Vice President of Luye Pharma Pharmacovigilance, Mr. Shi Zhe, Director of China Medical System Pharmaceutical Registration and Quality Management Division, Ms. Cai Fengqun, director of Sichuan Kelun Pharmaceutical Pharmacovigilance, and Mr. Wan Bangxi, the moderator, talked about the theme of “Win-win cooperation in healthcare industry and patient medication safety”. They varied in perspectives and presented a fruitful conversation.
Taimei Technology has been well awared of industry and customer needs after years of contact with more than a thousand customers and in-depth exploration of the industry. Mr. Bai Yongliang, the director of Taimei Technology Pharmacovigilance, said in the introduction of “Taimei Technology Pharmacovigilance Comprehensive Solutions”, the pharmacovigilance system keeps up with the development of regulations. Years of iterative updates made it increasingly mature and it can provide customers with the covering of entire drugs life cycle and the whole process of pharmacovigilance.
Pharmacovigilance leaders from different enterprises served by Taimei Technology share their personal experience in developing pharmacovigilance, including Mr. Zhang Caiquan, the head of Lunan Pharmaceutical Pharmacovigilance, Ms. Zhang Yan, the head of Pierre Faber Pharmacovigilance, Mr. Su Minshi, director of Xuanzhu Pharma pharmacovigilance, Mr. Chen Hongzhang, director of Tianjin Chase Sun Pharmacovigilance, Lan lili, director of Haisco Pharmaceutical Pharmacovigilance, and Ms. Wei Lianyan, the head of Techdow Pharma Pharmacovigilance.
In the “Bounded to Borderless” chapter in the afternoon of the summit, the chairman of PSM Beijing Foundation Mr. Zhang Xiaole, Big Data Analyst of China Electric Data Dr. Wan Min, General Manager of Wanfang Medical Dr. Zhang Xiumei, Partner of Prudentia Marcelo Diaz and Senior Director of Softium Ms. Jiang Wenxin shared their thoughts of triggering the far-reaching innovation of the pharmacovigilance by further cross-border collaboration from different industries and perspectives.